Broach Lifecare Hospital Regulatory Approval

Broach Lifecare Hospital Other Announcement

Broach Lifecare Hospital's Reg 32 statement shows Rs.307.50 lakh of IPO proceeds utilised as of 30 September 2026. The Audit Committee reported no deviation or variation.

Broach Lifecare Hospital H1 FY27 Results: Net Profit ₹0.1 Cr, Down 66.7% YoY

Broach Lifecare Hospital filed unaudited standalone half-year results to September 2026, reviewed by auditors. The filing includes a full results statement.

Key figure

Net profit ₹0.1 Cr · -66.7% YoY

Broach Lifecare Hospital Board Meeting Date

Broach Lifecare Hospital intimated BSE that its Board Meeting is scheduled for 31 Oct 2026 to consider half-year unaudited results. No other material decision has been announced yet.

Broach Lifecare Hospital Other Announcement

Broach Lifecare Hospital Ltd has submitted its quarterly shareholding pattern as per Regulation 31(1)(b) for the period ending September 30, 2026.

Broach Lifecare Hospital Business Update

Broach Lifecare Hospital has secured empanelment with ONGC and ESIC. Additionally, it expanded PMJAY services and completed its NABH accreditation inspection.

dialysis unit

5.0 beds

Broach Lifecare Hospital Management Change

Broach Lifecare Hospital Limited has appointed M/s. Rahul S Mithaiwala & Co. as the company's Secretarial Auditor effective September 30, 2026.

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.